title: Improved adherence expected with new HIV combo treatment.
authors.affiliation: Genentech. TMorrow@ManagedCareMag.com
authors.forename: Thomas
authors.initials: T
authors.lastname: Morrow
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D019380:Anti-HIV Agents / Q000191:economics / Q000627:therapeutic use*; D002219:Carbamates / Q000191:economics / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000191:economics / Q000627:therapeutic use*; D004338:Drug Combinations; D004348:Drug Labeling; D000069545:Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D055118:Medication Adherence; D008875:Middle Aged; D063065:Organophosphonates / Q000191:economics / Q000627:therapeutic use*; D015363:Quinolones / Q000191:economics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013844:Thiazoles / Q000191:economics / Q000627:therapeutic use*; D014481:United States
chemical_list: D019380:Anti-HIV Agents; D002219:Carbamates; D004338:Drug Combinations; D000069545:Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D063065:Organophosphonates; D015363:Quinolones; D013844:Thiazoles; D003841:Deoxycytidine; D000225:Adenine